Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Shivaani Kummar1,2, Mark Raffeld1, Lamin Juwara3, Yvonne Horneffer1, Agnes Strassberger1, Deborah Allen1, Seth M. Steinberg1, Annamaria Rapisarda4, Shawn D. Spencer4, William D. Figg1, Xiaohong Chen1, Ismail Baris Turkbey1, Peter Choyke1, Anthony J. Murgo2, James H. Doroshow1,2, and Giovanni Melillo4

Abstract

Purpose: Hypoxia-inducible factor 1 (HIF-1) α is frequently overexpressed in human tumors and is associated with angiogenesis and metastasis. Topotecan, a topoisomerase I inhibitor, has been shown to inhibit HIF-1α expression in preclinical models. We designed a pilot trial to measure HIF-1α inhibition in tumor biopsies from patients with advanced solid tumors overexpressing HIF-1α, after treatment with oral topotecan.

Experimental Design: Topotecan was administered orally at 1.6 mg/m² once daily for 5 days/week for 2 weeks, in 28-day cycles. Objectives were to determine inhibition of expression of HIF-1α and HIF-1 target genes in tumor; to assess tumor blood flow by dynamic contrast–enhanced magnetic resonance imaging (DCE-MRI); and to measure pharmacokinetics. Tumor biopsies were collected at baseline and during the second cycle of treatment.

Results: Sixteen patients were enrolled. The dose of topotecan was reduced to 1.2 mg/m²/day due to myelosuppression. Seven patients had paired tumor biopsies. In 4 patients, HIF-1α nuclear staining became undetectable after treatment (7.5%–50% staining at baseline). Decreased levels of VEGF and GLUT-1 mRNA were measured in 4 patients; the changes were concordant with reduction in HIF-1α in 3 patients. Decreased tumor blood flow and permeability were observed by DCE-MRI in 7 of 10 patients after 1 cycle. One patient had a partial response accompanied by inhibition of HIF-1α in tumor and reduction in tumor blood flow on DCE-MRI.

Conclusions: This multihistology, target assessment trial of a small molecule inhibitor of HIF-1α showed that topotecan could decrease HIF-1α expression in advanced solid tumors. Clin Cancer Res; 17(15); 5123–31. ©2011 AACR.
I enzyme on DNA, causing DNA damage and cell death in the presence of DNA replication. However, we have shown that topotecan also inhibits the accumulation of the α-subunit of HIF-1 by a mechanism independent of DNA replication-mediated DNA damage (11–13). Two features of the ability of topotecan to inhibit HIF-1α in vitro are relevant to the design of this clinical trial: the effect is rapidly reversible with removal of the drug (as early as 2 hours), and the daily addition of topotecan to cells cultured under hypoxic conditions significantly decreases the IC_{50} values for the inhibition of HIF-1α (11–14). Treatment of tumor-bearing animals with low-dose topotecan daily for 10 days resulted in the reduced expression of HIF-1α protein and HIF-1α-inducible genes, e.g., VEGF and GLUT-1, in tumor tissues (14). These findings suggest that protracted administration of topotecan may be necessary to achieve a sustained inhibition of HIF-1. Therefore, in this study we decided to administer the injectable formulation of topotecan orally at 1.6 mg/m^2/day for 5 days/week for 2 weeks, in 28-day cycles. This is lower than the per-day, US Food and Drug Administration–approved dosage of oral topotecan of 2.3 mg/m^2/day once daily for 5 consecutive days, every 21 days, but allowed chronic administration of a potentially safe dose of topotecan.

Based on these preclinical data, we initiated a pilot trial in patients with tumors overexpressing HIF-1α protein to determine whether chronic oral administration of topotecan inhibits HIF-1α expression in tumor biopsy samples; to assess tumor angiogenesis by dynamic contrast–enhanced magnetic resonance imaging (DCE-MRI); and to determine the pharmacokinetics of topotecan administered orally.

Patients and Methods

Eligibility criteria

Patients (age ≥ 18 years) were eligible if they had pathologically confirmed metastatic malignancy for which there were no acceptable standard therapies; had malignancy that expressed HIF-1α protein as measured by immunohistochemistry (IHC) on archival tissue (defined as ≥ 10% of cells showing positive nuclear staining for HIF-1α); had an Eastern Cooperative Oncology Group performance status ≤ 2; and had adequate organ and marrow function defined as absolute neutrophil count ≥1,500/μL, platelets ≥100,000/μL, total bilirubin ≤1.5 × the upper limit of normal (ULN), aspartate aminotransferase and/or alanine aminotransferase <2.5 × ULN, and creatinine <1.5 × ULN. Patients were required to have tumor lesions amenable to biopsy and be willing to undergo paired tumor biopsies.

Patients must have completed prior anticancer therapy at least 4 weeks before starting the study drug and have recovered to eligibility levels from toxicities of prior treatment. Patients were excluded if they had an uncontrolled intercurrent illness; were pregnant or lactating; had received treatment for brain metastases within the past 3 months; or had prior therapy with topotecan.

This trial was conducted after institutional review board approval. The protocol design and conduct followed all applicable regulations, guidances, and local policies. ClinicalTrials.gov Identifier NCT00182676.

**Translational Relevance**

Although hypoxia-inducible factor 1 (HIF-1) α is an exciting target for cancer therapy, the potential therapeutic effect of HIF-1α inhibition in human tumors remains to be shown. This pilot study is the first target-driven, multihistology clinical trial of a small molecule inhibitor of HIF-1α designed to evaluate inhibition of the target in paired tumor biopsies. The trial serves as a model for incorporating pharmacodynamic evaluation of target modulation in tumor tissue into the clinical development of putative small molecule inhibitors of HIF-1α. In a limited number of tumor samples from patients, we were able to show changes in expression of HIF-1α and HIF-1 target genes in response to chronic oral administration of the topoisomerase I inhibitor topotecan, which has been shown to inhibit HIF-1α in preclinical models.

**Trial design**

This was an open-label, pilot trial of oral topotecan in patients with refractory advanced solid neoplasms expressing HIF-1α as defined above. Topotecan was administered orally, initially at the dose of 1.6 mg/m^2 once daily for 5 consecutive days, followed by 2 days without drug, and then another 5 consecutive days of treatment; cycle length was 28 days. Restaging by radiologic imaging was carried out every 2 cycles until disease progression. Each vial of the injectable formulation obtained from commercial sources was reconstituted with 4 mL of bacteriostatic water to yield a drug concentration of 1 mg/mL in oral syringes stored at 4°C for up to 14 days. Immediately prior to administration, the appropriate dose was mixed with 30 mL of either apple, orange, or grape juice (acidic medium) and given orally.

Patients were asked to undergo a new tumor biopsy prior to the start of study treatment (baseline) and then at the end of treatment on cycle 2 (day 12 or 13 of cycle 2). All tumor biopsy samples were obtained from metastatic sites by experienced interventional radiologists. During each biopsy procedure, 2 cores of tumor tissue were obtained (18-gauge needle) from metastatic sites under CT guidance and processed for evaluation of HIF-1α expression. Patients were required to have tumor lesions amenable to biopsy and be willing to undergo paired tumor biopsies.

The dose of topotecan was reduced (dose level −1, 1.2 mg/m^2/day, or dose level −2, 0.9 mg/m^2/day) for grade 4...
thrombocytopenia, grade 4 neutropenia lasting longer than 5 days, and/or grade 3 nonhematologic toxicities (except nausea, vomiting, and diarrhea that responded to supportive measures). All toxicities had to resolve to grade ≤1 or pretreatment baseline levels prior to administering further therapy on study.

Safety and efficacy evaluations

History, physical examination, and complete blood counts with differential and serum chemistries were carried out at baseline, and complete blood counts were repeated once a week on treatment. Radiographic evaluation was carried out at baseline and every 2 cycles to assess tumor response based on the Response Evaluation Criteria in Solid Tumors version 1.0 (15).

Pharmacokinetics

Blood samples (7 mL) for topotecan pharmacokinetic analysis were collected on cycle 1 day 1 in tubes containing lithium heparin as anticoagulant. Samples were collected immediately prior to dosing, and at 0.5, 1, 1.5, 2, 3, 4, and 6 hours after administration of topotecan. Plasma concentrations of both the lactone (pharmacologically active form) and carboxylate forms of topotecan were determined simultaneously by high-performance liquid chromatography with fluorescence detection (see Supplementary Data) (16). Compartmental pharmacokinetic analysis was carried out on the first oral dose using WinNonlin, version 4.1 (Pharsight). Pharmacokinetic parameters of interest included maximum plasma concentration (C_{max}), time to maximum plasma concentration (T_{max}), area under the concentration-time curve from zero to infinity (AUC_{0-\infty}), apparent oral clearance (Cl/F), and terminal half-life (T_{1/2}). Absolute doses were used to calculate Cl/F.

Immunohistochemistry

An archived paraffin-embedded block, or a minimum of 5 unstained sections, was required for IHC analysis prior to enrollment. For enrollment purposes the archival material was scored solely as positive (defined as at least 10% of cells with positive nuclear staining for HIF-1α) or negative. Intensity of staining was noted, but not used as an entry parameter. Only patients whose tumors scored as positive were eligible for enrollment.

Tumor biopsies obtained on study were scored according to the nuclear staining for HIF-1α in tumor cells. The percentage of tumor cells showing positive staining for HIF-1α was calculated; cytoplasmic staining and positive stromal cells were not considered. If a patient had several slides with a range of positivity, the highest value was reported.

Immunohistochemistry for HIF-1α was carried out using clone H1667 (Novus Biologicals) at a dilution of 1:2,000. Prior to primary antibody incubation, the slides were subjected to a heat-induced antigen retrieval step consisting of 4 minutes of boiling in a solution of 0.1 mmol/L EDTA, in a microwavable pressure cooker (Nordicware) at full pressure. The primary antibody was incubated overnight, and detection was carried out with the CSA I detection kit (Dako) on an automated robot (Autostainer) according to the manufacturer’s recommendations. When necessary to reduce background staining, additional dilutions of the primary antibody up to 1:8,000 were used.

RNA extraction and real-time PCR analysis

After collection, tumor biopsy samples were submerged in RNAlater RNA Stabilization Reagent (Qiagen), kept at 4°C for 24 hours, and then stored at −20°C. Samples were subsequently disrupted and homogenized in RNA Lysis Buffer (RNeasy Mini Kit, Qiagen) using Fastprep (Lysing Matrix D columns, MP Biomedicals). Total RNA was extracted according to the manufacturer’s procedure. Genomic DNA was digested using RNase-Free DNase Set (Qiagen) during RNA extraction. RNA integrity was evaluated using RNA 6000 Nano Assay in an Agilent 2100 Bioanalyzer (Agilent Technologies).

RT-PCR was carried out using an RT-PCR kit (PE Biosystems) according to the manufacturer’s procedure. VEGF and GLUT-1 expression were assessed by real-time PCR using a 7500 Real-Time PCR System (Applied Biosystems). Typically, 5 ng of reverse-transcribed cDNA per sample was used to conduct real-time PCR in triplicate samples. Primers and probes used are listed in Supplementary Table S1.

Detection of 18S rRNA, used as internal control, was carried out using premixed reagents from Applied Biosystems. Detection of VEGF and 18S rRNA was carried out using TaqMan Universal PCR Master Mix (Applied Biosystems), whereas GLUT-1 detection was carried out using Sybr Green PCR Master Mix (Applied Biosystems). Values are expressed as percent change relative to pretreatment samples for each patient.

Statistical methods

For the purpose of sample size determination, there was one primary endpoint evaluated: expression of HIF-1α protein as determined by IHC. DCE-MRI was evaluated as a secondary endpoint. Results for the primary endpoint were scored on a continuous scale from 0 to 100 (based on the mean percent of cells that stain positive in each biopsy evaluated), and the changes between pretreatment and the end of treatment on cycle 2 were evaluated. Patients were considered evaluable to assess this primary objective if they completed treatment on cycles 1 and 2 and had paired biopsy specimens available for analysis. With 13 evaluable subjects, there would be 90% power to detect an effect equal to one standard deviation of the differences, using a two-tailed 0.05 alpha-level paired t-test. Because the HIF-1α differences were found to not be normally distributed, a Wilcoxon signed rank test was used instead. In addition, accrual up to 20 patients was permitted to allow for replacement of patients without paired biopsies.

Results

A total of 16 patients were enrolled; the median age was 54 years (Table 1). Patients were heavily pretreated, with a
of at least 2 cycles of therapy, and of these, 7 had paired tumor biopsies and were considered evaluable per protocol.

The first 2 patients received the dose of 1.6 mg/m²/day, and developed grade 4 neutropenia. The dose of topotecan was reduced for subsequent patients to 1.2 mg/m²/day, because the intent was to develop a regimen of oral topotecan that could be safely administered chronically without severe toxicity. There were no unexpected toxicities, with the most common toxicity being myelosuppression, even at the lower dose of 1.2 mg/m²/day (Table 2). A 63-year-old man (patient 10) with metastatic small cell lung cancer, status postdisease progression following 4 cycles of cisplatin and etoposide, received oral topotecan at 1.2 mg/m²/day. He had a partial response to study treatment lasting 6 cycles, with evidence of inhibition of HIF-1α in tumor biopsy samples (Fig. 1A), and a reduction in tumor blood flow on DCE-MRI (Fig. 2).

**HIF-1α expression**

Of the 16 patients who were eligible for the study (HIF-1α nuclear staining in ≥ 10% of cancer cells from archival tissue), 15 underwent a baseline (pretreatment) biopsy. In these patients, the average percentage ± SD of HIF-1α-positive cells in the archival tissue was 26.4% ± 22.7% (range, 10%–90%) and in the baseline biopsy was 22.1% ± 22.4% (range, 0%–70%), suggesting a good correlation between archival tissue and biopsy sample (r = 0.896). Two of 12 patients whose archival tissue was HIF-1α positive (50% and 10%, respectively) had baseline biopsy samples that did not show any nuclear HIF-1α staining. Seven patients received baseline and posttreatment biopsies and were evaluable for the primary endpoint of the study (Fig. 1). Although there was a decrease in the average percentage of HIF-1α-positive cells in the posttreatment biopsy samples compared with baseline, the difference was not statistically significant (P = 0.16; Fig. 1B). However, in 4 patients, no HIF-1α nuclear staining was detectable in the posttreatment biopsies, compared with a range of HIF-1α-positive cells of 7.5% to 50% in the baseline biopsies for these patients (Figs. 1A and 1C). In 2 patients, there was no change in the percent of HIF-1α-positive cells between the baseline and posttreatment biopsies.

**Expression of HIF-1 target genes**

Evaluation of mRNA expression of HIF-1 target genes was carried out in 6 patients for whom RNA was available from paired biopsies. VEGF mRNA expression was decreased in 5 of the 6 evaluable patients (Fig. 3A). Expression of VEGF mRNA, relative to 100% used as an arbitrary value for baseline levels, ranged from 8.5% to 148% in posttreatment biopsies. Patients 1 and 3, for whom no decrease in HIF-1α protein was observed by IHC, had decreased levels of VEGF mRNA expression by 91.5%

---

**Table 1. Patient characteristics**

<table>
<thead>
<tr>
<th>Number of patients enrolled/evaluable</th>
<th>16/7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>9/7</td>
</tr>
<tr>
<td>Median age (range), years</td>
<td>54 (26–70)</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Median number of prior therapies (range)</td>
<td>4 (2–8)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
</tr>
<tr>
<td>Colorectal carcinoma</td>
<td>5</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>2</td>
</tr>
<tr>
<td>Adrenocortical cancer</td>
<td>2</td>
</tr>
<tr>
<td>Sarcoma</td>
<td></td>
</tr>
<tr>
<td>Alveolar soft part sarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Melanoma</td>
<td>1</td>
</tr>
<tr>
<td>Small cell lung cancer</td>
<td>1</td>
</tr>
<tr>
<td>Pancreas adenocarcinoma</td>
<td>1</td>
</tr>
<tr>
<td>Head and neck squamous cell cancer</td>
<td>1</td>
</tr>
<tr>
<td>Bladder transitional cell cancer</td>
<td>1</td>
</tr>
</tbody>
</table>

**Table 2. Adverse events, by patient, grade 2 or greater, and at least possibly related to topotecan**

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Grade of adverse event by patient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Anemia</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3</td>
</tr>
<tr>
<td>Fatigue</td>
<td></td>
</tr>
<tr>
<td>Leucopenia</td>
<td>2</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>3</td>
</tr>
<tr>
<td>Nausea</td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>4</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>2</td>
</tr>
</tbody>
</table>

**NOTE:** Patients 1 and 2 received 1.6 mg/m²/day topotecan; all other patients received 1.2 mg/m²/day topotecan.
Figure 1. Percentage of HIF-1α-positive cells in samples from baseline and posttreatment tumor biopsies from 7 evaluable patients, reported per patient (A) and as mean ± SD (B). Immunohistochemistry staining for HIF-1α shown for patient 4 (breast cancer) at baseline and after 2 cycles of topotecan (C).

Figure 2. K\text{trans} (upper row) and k\text{ep} (lower row) color maps obtained from DCE-MRI of a 63-year-old man (patient 10) with liver metastases before (A, C) and after treatment during cycle 2 (B, D) show significant reduction in values consistent with response to therapy (arrows); patient had partial response lasting 6 cycles.
and 35%, respectively, compared with baseline biopsies. Patient 5 had no decrease in VEGF mRNA expression, despite a decrease in HIF-1α protein to levels undetectable by IHC in the posttreatment biopsy.

Changes in GLUT-1 mRNA expression (Fig. 3B) were fairly concordant with VEGF mRNA levels. In particular, 4 of 6 patients had decreased levels of both VEGF and GLUT-1 mRNA in the posttreatment biopsies. Patient 5 did not have a decrease in either VEGF or GLUT-1 mRNA expression, and patient 3 had a modest decrease in both VEGF and GLUT-1 by 34.9% and 9.2%, respectively.

**Dynamic contrast–enhanced magnetic resonance imaging**

Twelve patients had DCE-MRI scans at baseline. Lesions were found in the liver (5 patients), lung (2 patients), retroperitoneum (2 patients), chest wall (1 patient), axilla (1 patient), and mesentery (1 patient). Eleven patients had at least 1 follow-up DCE-MRI scan after treatment, and 6 had 2 follow-up scans. In 1 patient, the first follow-up scan was not adequate due to an unsuccessful contrast media injection. Decreases in both Ktrans and kep compared with baseline scan were seen in 7 of 10 patients who had follow-up DCE-MRI at the first time point and in 4 of 6 patients who had follow-up DCE-MRI at the second time point (Figs. 4A and 4B).

**Pharmacokinetics**

Eleven of the 16 patients enrolled had sufficient pharmacokinetic data available for compartmental analysis. Nine of these patients received topotecan at the dose of 1.2 mg/m² and 2 at 1.6 mg/m², orally in an acidic medium (apple, orange, or grape juice) to prevent hydrolysis into the open/carboxylate form. The mean plasma concentration versus time curves for the closed (lactone) and open (carboxylate) forms of topotecan are shown in Supplementary Fig. S1. The parameters were successfully estimated using a one-compartment model with first-order input. Three patients required a lag-time model to fit the carboxylate plasma-concentration data. All parameters were estimated assuming first-order absorption. Administration of topotecan at 1.2 mg/m² resulted in higher plasma concentrations for the lactone than the carboxylate form, resulting in 1.5-fold higher Cmax (P = 0.019, Mann–Whitney test) and 1.5-fold higher AUC0–∞ (P = 0.050, Mann–Whitney test), whereas the Tmax for the appearance of the carboxylate form was 1.27 times longer than the lactone form (P = 0.040, Mann–Whitney test; Supplementary Table S2). There were no significant differences in terminal T1/2 between the 2 topotecan forms (Supplementary Table S2). Administration of topotecan at 1.6 mg/m² showed a slightly delayed absorption for both the lactone and carboxylate forms, resulting in a lower Cmax at later Tmax and lower overall exposure (AUC0–∞/nominal dose) compared with the 1.2 mg/m² dose group, although given the sample size (n = 2), there was limited power to detect significant differences in topotecan absorption or disposition at the higher dose.

The plasma exposure of the active lactone form was correlated with DCE-MRI parameters, Ktrans and kep, the change in percent expression of VEGF and GLUT-1 mRNA, and the change in percentage of HIF-1α–positive cells. No correlation was found between pharmacokinetic metrics of plasma exposure and both the MRI parameters or the change in HIF-1α–positive cells. However, relatively strong correlations were found between the AUC0–∞ and change in percent expression of VEGF (R² = 0.70) and GLUT-1 (R² = 0.87; Supplementary Fig. S2), but not with the nominal dose (R² = 0.08 and 0.10, respectively), for those patients with a decrease in mRNA expression and evaluable pharmacokinetics (n = 4). The plasma exposure revealed no correlation with dose, over the nominal dose range of 1.3 to 3.3 mg (R² = 0.016), suggestive of reduced bioavailability (i.e., slight trend observed of an increase in Cl/F with increasing doses; Supplementary Fig. S3).
with modulation of tumor blood flow and permeability, an expected outcome of HIF-1 inhibition in tumor tissue, dependent, at least in part, on inhibition of VEGF, a known HIF-1 target gene.

Concordant results between levels of HIF-1α protein by IHC and VEGF mRNA expression were only observed for 3 of 6 evaluable patients. In 2 patients, a decrease in VEGF mRNA was detected in the absence of changes in HIF-1α protein levels by IHC, and in 1 patient, decreased levels of HIF-1α by IHC did not correlate with a decrease in VEGF mRNA expression. In contrast, there was a good correlation between VEGF and GLUT-1 mRNA levels between pre- and posttreatment biopsies. These discrepancies, which remain difficult to interpret given the small number of patients, may be due to HIF-1α-independent regulation of gene expression, (e.g., HIF-2–dependent or HIF-independent) and/or sampling variability, due to heterogeneous expression of HIF-1 in solid tumors. Alternatively, inhibitory effects on mRNA expression of HIF-1 target genes may last longer than those detectable at the protein level, given the short half-life and rapid turnover of HIF-1α with changes in oxygen concentration. Thus, identification and validation of the most reliable and predictive pharmacodynamic endpoint reflective of HIF-1α modulation remains to be defined in future studies.

Of 16 patients enrolled on study, only 7 received paired biopsies, due to patients experiencing progressive disease before a second biopsy could be carried out. Patients were selected based on an arbitrary threshold of ≥10% HIF-1α–positive cells in archival tumor tissue, without scoring cytoplasmic staining and positive stromal cells. In an analysis by Zhong and colleagues of HIF-1α expression in 179 tumor specimens from primary or metastatic cancers, approximately 40% of metastatic lesions expressed HIF-1α in ≥10% of cells (1). HIF-1α overexpression has also been associated with treatment failure and patient mortality in a variety of cancers (4–9). Given the heterogeneous expression of HIF-1α in human tumors and the known correlation between HIF-1 overexpression and poor prognosis and response to treatment, this study may have selected patients with unfavorable prognostic features.

Pharmacokinetic analysis revealed that oral administration of topotecan at 1.2 mg/m² resulted in higher plasma concentrations for the lactone (pharmacologically active form) than the carboxylate form. The reversible hydrolysis from lactone to carboxylate is largely pH dependent. Below pH 4, topotecan exists almost exclusively as lactone; however, at pH 7.2 the carboxylate is three times as likely to be present (17). The mean T½ of topotecan lactone at a 1.2 mg/m² dose (3.86 hours) was comparable with 4.22 hours previously reported for topotecan lactone at the same dose from a phase I clinical trial by Gerrits and colleagues (18), in which a similar oral formulation of injectable topotecan was administered.

Efforts to identify small molecule inhibitors of HIF-1 have primarily focused on cell-based high-throughput screening assays. The majority of HIF-1 inhibitors
described so far lack specificity, raising the question as to whether HIF-1 inhibition does indeed contribute to the clinical activity of these agents (19). In addition, although genetic approaches have shown that HIF-1 deletion is associated with impaired tumor growth in experimental models, the potential therapeutic effects of HIF-1 inhibition in human tumors remains to be shown. Therefore, it is imperative that early clinical development of putative small molecule inhibitors of HIF-1 be guided by pharmacodynamic evaluation of target modulation in tumor tissue.

Topotecan was used in this study as a prototype HIF-1 inhibitor. However, its short half-life and clinical toxicities argue against its use on a chronic schedule to inhibit signal-transduction pathways. In addition, topotecan has been tested in renal cell cancer, a disease in which HIF plays an important role, and was found to be inactive, although it was used on a classic cytotoxic schedule (1.5 mg/m² IV daily × 5 every 28 days; Ref. 20). Topoisomerase I inhibitors with longer half-lives and increased tumor retention (21) may be more suitable for HIF-1 inhibition in the clinic. Finally, single-agent inhibition of HIF-1 may not be sufficient to achieve meaningful therapeutic responses, at least in part due to the limited and heterogeneous expression of HIF-1 in solid tumors. HIF-1 expression has been implicated in mediating resistance to chemotherapy and radiation therapy, suggesting that combination studies should be pursued to fully explore the potential therapeutic effects of HIF-1 inhibition in human cancers.

This study emphasizes issues related to target-driven clinical trials that not only relate specifically to evaluation of HIF-1 but also, in general, to biomarker evaluation during exploratory clinical studies. Extensive evaluation of target modulation in preclinical models and adequate assay development are essential for a successful clinical study. As discussed above, evaluation of HIF-1α expression poses unique problems due to its heterogeneous expression in tumor tissue. However, a global evaluation of tissue endpoints associated with target modulation, supported by validated assay development, is imperative to provide proof-of-principle in mechanism-based drug development.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Gina Uhlenbrauck (SAIC-Frederick, Inc.) for editorial support. We thank Sukyung Woo, Ph.D. (Center for Cancer Research, National Cancer Institute) for assistance in pharmacokinetic analysis.

Grant Support
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN26120080000E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported by the Center for Cancer Research and the Division of Cancer Treatment and Diagnosis of the National Cancer Institute.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 14, 2011; revised May 19, 2011; accepted May 31, 2011; published OnlineFirst June 14, 2011.
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 α in Advanced Solid Tumors

Shivaani Kummar, Mark Raffeld, Lamin Juwara, et al.

Clin Cancer Res 2011;17:5123-5131. Published OnlineFirst June 14, 2011.